{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:23:17Z","timestamp":1778077397603,"version":"3.51.4"},"reference-count":35,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21402012"],"award-info":[{"award-number":["21402012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21907010"],"award-info":[{"award-number":["21907010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["201901D211465"],"award-info":[{"award-number":["201901D211465"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["201801D221082"],"award-info":[{"award-number":["201801D221082"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004311","name":"Shanxi \u201c1331 Project\u201d Key Innovative Research Team, and Undergraduate Innovation and Entrepreneurship Project of Shanxi Province","doi-asserted-by":"publisher","award":["2019603"],"award-info":[{"award-number":["2019603"]}],"id":[{"id":"10.13039\/501100004311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2020,6,14]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The third-generation irreversible Epidermal Growth Factor Receptor (EGFR) Tyrosine\nKinase Inhibitors (TKIs) inhibit the T790M mutation while sparing EGFRWT. However, the C797S point mutation\nconfers resistance to existing irreversible EGFRT790M inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Novel EGFRT790M inhibitors were designed through hybridization of quinoline and anilinopyrimidine,\nand biologically evaluated their antiproliferative activity against Non-Small Cell Lung Cancer (NSCLC) cell\nlines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The target compounds 11a-h were synthesized and structurally characterized with 1H, 13C Nuclear\nMagnetic Resonance (NMR) spectroscopy and High-Resolution Mass Spectrometry (HRMS). Their inhibitory\neffects on tumor cell proliferation and EGFR kinase were biologically evaluated. Additionally, molecular docking\nstudies were also performed on the representative typical EGFRT790M inhibitor.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Most of the evaluated compounds displayed moderate antiproliferative activity on H1975 cells with\nEGFRL858R\/T790M. However, compound 11a (IC50 = 2.235 \u00b1 0.565\u03bcM) showed stronger inhibition than gefitinib\n(IC50 = 8.830 \u00b1 0.495\u03bcM) in concentration- and time-dependent manner. Moreover, compound 11a exhibited\nweaker inhibitory activities on cells with EGFRWT. Specifically, compound 11a strongly suppressed\nEGFRL858R\/T790M (IC50 = 0.515 \u00b1 0.011\u03bcM) relative to EGFRWT (IC50 = 0.913 \u00b1 0.068\u03bcM). Furthermore, molecular\ndocking studies demonstrated its strong binding contacts with the EGFRT790M enzyme through hydrogen\nbonds and other non-bonded interactions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Taken together, these results indicate that the hybrid of quinoline and anilinopyrimidine 11a, could\nbe a potential inhibitor of EGFRT790M in NSCLC, which warrants further in-depth studies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620666200302113206","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T13:14:41Z","timestamp":1583154881000},"page":"724-733","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines"],"prefix":"10.2174","volume":"20","author":[{"given":"Chun","family":"Han","sequence":"first","affiliation":[{"name":"Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahong","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Biology, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lintao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Changzhi University, Shanxi, Changzhi 046011, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"Bray F.","year":"2018","unstructured":"Bray F.; Ferlay J.; Soerjomataram I.; Siegel R.L.; Torre L.A.; Jemal A.; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018,68(6),394-424","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"Herbst R.S.","year":"2008","unstructured":"Herbst R.S.; Heymach J.V.; Lippman S.M.; Lung cancer. N Engl J Med 2008,359(13),1367-1380","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/cancers7020816","volume":"7","author":"Rothschild S.I.","year":"2015","unstructured":"Rothschild S.I.; Targeted therapies in non-small cell lung cancer-beyond EGFR and ALK. Cancers (Basel) 2015,7(2),930-949","journal-title":"Cancers (Basel)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.drudis.2017.10.004","volume":"23","author":"Singh M.","year":"2018","unstructured":"Singh M.; Jadhav H.R.; Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today 2018,23(3),745-753","journal-title":"Drug Discov Today"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"7525","DOI":"10.1158\/0008-5472.CAN-05-1257","volume":"65","author":"Johnson B.E.","year":"2005","unstructured":"Johnson B.E.; J\u00e4nne P.A.; Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005,65(17),7525-7529","journal-title":"Cancer Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"Sharma S.V.","year":"2007","unstructured":"Sharma S.V.; Bell D.W.; Settleman J.; Haber D.A.; Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007,7(3),169-181","journal-title":"Nat Rev Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","volume":"11","author":"Barker A.J.","year":"2001","unstructured":"Barker A.J.; Gibson K.H.; Grundy W.; Godfrey A.A.; Barlow J.J.; Healy M.P.; Woodburn J.R.; Ashton S.E.; Curry B.J.; Scarlett L.; Henthorn L.; Richards L.; Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001,11(14),1911-1914","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=8","first-page":"4838","volume":"57","author":"Moyer J.D.","year":"1997","unstructured":"Moyer J.D.; Barbacci E.G.; Iwata K.K.; Arnold L.; Boman B.; Cunningham A.; DiOrio C.; Doty J.; Morin M.J.; Moyer M.P.; Neveu M.; Pollack V.A.; Pustilnik L.R.; Reynolds M.M.; Sloan D.; Theleman A.; Miller P.; Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997,57(21),4838-4848","journal-title":"Cancer Res"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"Pao W.","year":"2005","unstructured":"Pao W.; Miller V.A.; Politi K.A.; Riely G.J.; Somwar R.; Zakowski M.F.; Kris M.G.; Varmus H.; Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005,2(3)","journal-title":"PLoS Med"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1200\/JCO.2011.40.9433","volume":"30","author":"Ramalingam S.S.","year":"2012","unstructured":"Ramalingam S.S.; Blackhall F.; Krzakowski M.; Barrios C.H.; Park K.; Bover I.; Seog Heo D.; Rosell R.; Talbot D.C.; Frank R.; Letrent S.P.; Ruiz-Garcia A.; Taylor I.; Liang J.Q.; Campbell A.K.; O\u2019Connell J.; Boyer M.; Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2012,30(27),3337-3344","journal-title":"J Clin Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1200\/JCO.2007.11.1336","volume":"25","author":"J\u00e4nne P.A.","year":"2007","unstructured":"J\u00e4nne P.A.; von Pawel J.; Cohen R.B.; Crino L.; Butts C.A.; Olson S.S.; Eiseman I.A.; Chiappori A.A.; Yeap B.Y.; Lenehan P.F.; Dasse K.; Sheeran M.; Bonomi P.D.; Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 2007,25(25),3936-3944","journal-title":"J Clin Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00280-011-1738-1","volume":"69","author":"Murakami H.","year":"2012","unstructured":"Murakami H.; Tamura T.; Takahashi T.; Nokihara H.; Naito T.; Nakamura Y.; Nishio K.; Seki Y.; Sarashina A.; Shahidi M.; Yamamoto N.; Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy\/erlotinib\/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 2012,69(4),891-899","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","volume":"28","author":"Sequist L.V.","year":"2010","unstructured":"Sequist L.V.; Besse B.; Lynch T.J.; Miller V.A.; Wong K.K.; Gitlitz B.; Eaton K.; Zacharchuk C.; Freyman A.; Powell C.; Ananthakrishnan R.; Quinn S.; Soria J.C.; Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010,28(18),3076-3083","journal-title":"J Clin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fmed.2016.00076","volume":"3","author":"Sullivan I.","year":"2017","unstructured":"Sullivan I.; Planchard D.; Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med (Lausanne) 2017,3,76","journal-title":"Front Med (Lausanne)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nature08622","volume":"462","author":"Zhou W.","year":"2009","unstructured":"Zhou W.; Ercan D.; Chen L.; Yun C.H.; Li D.; Capelletti M.; Cortot A.B.; Chirieac L.; Iacob R.E.; Padera R.; Engen J.R.; Wong K.K.; Eck M.J.; Gray N.S.; J\u00e4nne P.A.; Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009,462(7276),1070-1074","journal-title":"Nature"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","volume":"3","author":"Walter A.O.","year":"2013","unstructured":"Walter A.O.; Sjin R.T.; Haringsma H.J.; Ohashi K.; Sun J.; Lee K.; Dubrovskiy A.; Labenski M.; Zhu Z.; Wang Z.; Sheets M.; St Martin T.; Karp R.; van Kalken D.; Chaturvedi P.; Niu D.; Nacht M.; Petter R.C.; Westlin W.; Lin K.; Jaw-Tsai S.; Raponi M.; Van Dyke T.; Etter J.; Weaver Z.; Pao W.; Singh J.; Simmons A.D.; Harding T.C.; Allen A.; Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013,3(12),1404-1415","journal-title":"Cancer Discov"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1021\/jm500973a","volume":"57","author":"Finlay M.R.","year":"2014","unstructured":"Finlay M.R.; Anderton M.; Ashton S.; Ballard P.; Bethel P.A.; Box M.R.; Bradbury R.H.; Brown S.J.; Butterworth S.; Campbell A.; Chorley C.; Colclough N.; Cross D.A.; Currie G.S.; Grist M.; Hassall L.; Hill G.B.; James D.; James M.; Kemmitt P.; Klinowska T.; Lamont G.; Lamont S.G.; Martin N.; McFarland H.L.; Mellor M.J.; Orme J.P.; Perkins D.; Perkins P.; Richmond G.; Smith P.; Ward R.A.; Waring M.J.; Whittaker D.; Wells S.; Wrigley G.L.; Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014,57(20),8249-8267","journal-title":"J Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/med.21488","volume":"38","author":"Lu X.","year":"2018","unstructured":"Lu X.; Yu L.; Zhang Z.; Ren X.; Smaill J.B.; Ding K.; Targeting EGFR and EGFR resistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev 2018,38(5),1550-1581","journal-title":"Med Res Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejmech.2013.05.026","volume":"66","author":"Han C.","year":"2013","unstructured":"Han C.; Huang Z.; Zheng C.; Wan L.; Lai Y.; Peng S.; Ding K.; Ji H.; Zhang Y.; Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors. Eur J Med Chem 2013,66,82-90","journal-title":"Eur J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1021\/jm400463q","volume":"56","author":"Han C.","year":"2013","unstructured":"Han C.; Huang Z.; Zheng C.; Wan L.; Zhang L.; Peng S.; Ding K.; Ji H.; Tian J.; Zhang Y.; Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. J Med Chem 2013,56(11),4738-4748","journal-title":"J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejmech.2014.02.032","volume":"77","author":"Han C.","year":"2014","unstructured":"Han C.; Wan L.; Ji H.; Ding K.; Huang Z.; Lai Y.; Peng S.; Zhang Y.; Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. Eur J Med Chem 2014,77,75-83","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"Thress K.S.","year":"2015","unstructured":"Thress K.S.; Paweletz C.P.; Felip E.; Cho B.C.; Stetson D.; Dougherty B.; Lai Z.; Markovets A.; Vivancos A.; Kuang Y.; Ercan D.; Matthews S.E.; Cantarini M.; Barrett J.C.; J\u00e4nne P.A.; Oxnard G.R.; Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015,21(6),560-562","journal-title":"Nat Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","volume":"5","author":"Piotrowska Z.","year":"2015","unstructured":"Piotrowska Z.; Niederst M.J.; Karlovich C.A.; Wakelee H.A.; Neal J.W.; Mino-Kenudson M.; Fulton L.; Hata A.N.; Lockerman E.L.; Kalsy A.; Digumarthy S.; Muzikansky A.; Raponi M.; Garcia A.R.; Mulvey H.E.; Parks M.K.; DiCecca R.H.; Dias-Santagata D.; Iafrate A.J.; Shaw A.T.; Allen A.R.; Engelman J.A.; Sequist L.V.; Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015,5(7),713-722","journal-title":"Cancer Discov"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejmech.2018.10.035","volume":"161","author":"Chu X.M.","year":"2019","unstructured":"Chu X.M.; Wang C.; Liu W.; Liang L.L.; Gong K.K.; Zhao C.Y.; Sun K.L.; Quinoline and quinolone dimers and their biological activities: An overview. Eur J Med Chem 2019,161,101-117","journal-title":"Eur J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3390\/molecules21080986","volume":"21","author":"Ramann G.A.","year":"2016","unstructured":"Ramann G.A.; Cowen B.J.; Recent advances in metal-free quinoline synthesis. Molecules 2016,21(8),986","journal-title":"Molecules"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejmech.2019.05.088","volume":"178","author":"Su T.","year":"2019","unstructured":"Su T.; Zhu J.; Sun R.; Zhang H.; Huang Q.; Zhang X.; Du R.; Qiu L.; Cao R.; Design, synthesis and biological evaluation of new quinoline derivatives as potential antitumor agents. Eur J Med Chem 2019,178,154-167","journal-title":"Eur J Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ejmech.2017.10.046","volume":"143","author":"El Shehry M.F.","year":"2018","unstructured":"El Shehry M.F.; Ghorab M.M.; Abbas S.Y.; Fayed E.A.; Shedid S.A.; Ammar Y.A.; Quinoline derivatives bearing pyrazole moiety: Synthesis and biological evaluation as possible antibacterial and antifungal agents. Eur J Med Chem 2018,143,1463-1473","journal-title":"Eur J Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1021\/acs.jmedchem.9b00115","volume":"62","author":"Musharrafieh R.","year":"2019","unstructured":"Musharrafieh R.; Zhang J.; Tuohy P.; Kitamura N.; Bellampalli S.S.; Hu Y.; Khanna R.; Wang J.; Discovery of quinoline analogues as potent antivirals against Enterovirus D68 (EV-D68). J Med Chem 2019,62(8),4074-4090","journal-title":"J Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2174\/1389557514666140220123226","volume":"14","author":"Gryz\u0142o B.","year":"2014","unstructured":"Gryz\u0142o B.; Kulig K.; Quinoline--a promising fragment in the search for new antimalarials. Mini Rev Med Chem 2014,14(4),332-344","journal-title":"Mini Rev Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.bmc.2006.02.039","volume":"14","author":"Chen Y.L.","year":"2006","unstructured":"Chen Y.L.; Zhao Y.L.; Lu C.M.; Tzeng C.C.; Wang J.P.; Synthesis, cytotoxicity, and anti-inflammatory evaluation of 2-(furan-2-yl)-4-(phenoxy)quinoline derivatives. Part 4. Bioorg Med Chem 2006,14(13),4373-4378","journal-title":"Bioorg Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejmech.2018.11.026","volume":"164","author":"Nainwal L.M.","year":"2019","unstructured":"Nainwal L.M.; Tasneem S.; Akhtar W.; Verma G.; Khan M.F.; Parvez S.; Shaquiquzzaman M.; Akhter M.; Alam M.M.; Green recipes to quinoline: A review. Eur J Med Chem 2019,164,121-170","journal-title":"Eur J Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1476-4598-3-21","volume":"3","author":"Nunes M.","year":"2004","unstructured":"Nunes M.; Shi C.; Greenberger L.M.; Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 2004,3(1),21-27","journal-title":"Mol Cancer Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","volume":"64","author":"Rabindran S.K.","year":"2004","unstructured":"Rabindran S.K.; Discafani C.M.; Rosfjord E.C.; Baxter M.; Floyd M.B.; Golas J.; Hallett W.A.; Johnson B.D.; Nilakantan R.; Overbeek E.; Reich M.F.; Shen R.; Shi X.; Tsou H.R.; Wang Y.F.; Wissner A.; Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004,64(11),3958-3965","journal-title":"Cancer Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/00397911.2013.805230","volume":"44","author":"Jin J.W.","year":"2014","unstructured":"Jin J.W.; Zhang L.; Meng G.R.; Zhu J.H.; Zhang Q.; Facile and efficient oxidation of quinazolines into quinazolin-4(3H)-ones by peracetic acid. Synth Commun 2014,44(3),346-351","journal-title":"Synth Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bioorg.2018.01.035","volume":"77","author":"Liu Z.","year":"2018","unstructured":"Liu Z.; Wang L.; Feng M.; Yi Y.; Zhang W.; Liu W.; Li L.; Liu Z.; Li Y.; Ma X.; New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers. Bioorg Chem 2018,77,593-599","journal-title":"Bioorg Chem"}],"container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179852","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T09:29:07Z","timestamp":1596360547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179852\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,14]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,14]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620666200302113206","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,14]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}